Table 1. Clinical and biological characteristics of AML patients.

Patient	Age/sex	Previous malignant disease, present disease status	FAB classification	Membrane molecule expressiona (%)				Mutations karyotypeb	Clinical response to treatmentc	Survival in daysd
				CD11b	CD15	CD71	CD34
				Day 0/2/7
1	68/F	MDS, 1st relapse	M1	9/13/19	2/3/4	17/30/34	5/12/6	FLT3-ITD, CEBPA	A	105
4	60/M	2nd relapse	M4	32/40/53	10/17/21	8/4/3	66/67/89	FLT3-ITD	—	7
5	50/F	Li-Fraumeni	M1	3/5/5	2/2/2	19/18/29	77/82/82	Complex karyotype	—	34
9	74/M	De novo	M0	9/10/10	0/0/0	41/43/42	67/74/59	None	—	112
12e	61/F	MDS, 1st relapse	M1	82/79/77	51/60/51	2/3/3	44/43/47	Complex karyotype	A	644
13	80/F	De novo	M2	29/25/53	2/1/0	41/36/66	48/45/50	FLT3 ITD, NPM1	B	8
14	78/M	MDS	M1	5/9/12	3/6/5	11/8/11	58/78/43	ND	A+B	55
15	86/M	De novo	M4	ND	ND	ND	42/ND/23	ND	A+B	58
16	67/M	MDS, 1st relapse	ND	40/14/72	51/28/47	8/0/2	32/48/48	FLT3-ITD, CEBPA	B	23
21	70/F	Chemotherapy	M4	44/41/25	37/39/30	2/1/1	11/16/26	NPM1	B	15
23	68/M	Myelofibrosis	M1	8/6/24	2/6/11	23/18/17	80/84/86	FLT3-TDK	B	70

Abbreviations: AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; ND, not determined.

^aThe results are presented as the percentage of positive cells. Differences exceeding 10% after 7 days are shown in bold.

^bKaryotype is normal if not other indicated.

^cResponses were classified as either peripheral blood normal cell counts (A) or decreased circulating AML blasts (B).

^dSurvival from start of treatment.

^ePatients showing hematological improvement according to the MDS criteria.